Literature DB >> 9865306

Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient.

N Basara1, W I Blau, M G Kiehl, E Römer, M Rudolphi, M Bischoff, D Kirsten, H Sanchez, S Günzelmann, A A Fauser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9865306     DOI： 10.1016/s0041-1345(98)01351-7

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  10 in total

1.  A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease.

Authors:  Chie Onishi; Kazuteru Ohashi; Takeshi Sawada; Mikako Nakano; Takeshi Kobayashi; Takuya Yamashita; Hideki Akiyama; Hisashi Sakamaki
Journal:  Int J Hematol       Date:  2010-03-10       Impact factor: 2.490

2.  Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan.

Authors:  Nozomu Kawashima; Minako Iida; Ritsuro Suzuki; Takahiro Fukuda; Yoshiko Atsuta; Yoshiko Hashii; Masami Inoue; Masao Kobayashi; Hiromasa Yabe; Keiko Okada; Souichi Adachi; Yuki Yuza; Keisei Kawa; Koji Kato
Journal:  Int J Hematol       Date:  2019-01-29       Impact factor: 2.490

3.  Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan.

Authors:  Minako Iida; Takahiro Fukuda; Kazuhiro Ikegame; Satoshi Yoshihara; Hiroyasu Ogawa; Shuichi Taniguchi; Akiyoshi Takami; Yasunobu Abe; Masayuki Hino; Tetsuya Etou; Yasunori Ueda; Toshiaki Yujiri; Toshimitsu Matsui; Atsuo Okamura; Junji Tanaka; Yoshiko Atsuta; Yoshihisa Kodera; Ritsuro Suzuki
Journal:  Int J Hematol       Date:  2011-04-05       Impact factor: 2.490

Review 4.  Management of acute graft-versus-host disease in children.

Authors:  Paul A Carpenter; Margaret L Macmillan
Journal:  Pediatr Clin North Am       Date:  2010-02       Impact factor: 3.278

5.  Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease.

Authors:  Akiyoshi Takami; Kanako Mochizuki; Hirokazu Okumura; Satsuki Ito; Yukio Suga; Hirohito Yamazaki; Masahide Yamazaki; Yukio Kondo; Hidesaku Asakura; Shinji Nakao
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

Review 6.  Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects.

Authors:  Myriam N Bouchlaka; Doug Redelman; William J Murphy
Journal:  Immunotherapy       Date:  2010-05       Impact factor: 4.196

7.  Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation.

Authors:  Franck Saint-Marcoux; Bernard Royer; Jean Debord; Fabrice Larosa; Faezeh Legrand; Eric Deconinck; Jean-Pierre Kantelip; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Mycophenolic acid derivative 118 improves outcome of skin grafts by suppressing IL-17 production.

Authors:  Fang-yuan Kong; Wei Chen; Shi-jun He; Ze-min Lin; Xin Li; Xiao-hui Zhang; Xiao-qian Yang; Feng-hua Zhu; Xian-kun Tong; Yu Zhou; Wei Tang; Wen-hu Duan; Jian-ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2013-05-06       Impact factor: 6.150

Review 9.  Adverse events in second- and third-line treatments for acute and chronic graft-versus-host disease: systematic review.

Authors:  Vladica M Velickovic; Emily McIlwaine; Rongrong Zhang; Tim Spelman
Journal:  Ther Adv Hematol       Date:  2020-12-08

10.  Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Xiaomei Chen; Chunyan Wang; Jin Yin; Jinhuan Xu; Jia Wei; Yicheng Zhang
Journal:  PLoS One       Date:  2015-08-31       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.